Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECP with UVADEX for GvHD Prevention
NCT00054600Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen in graft-versus-host disease (GVHD), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Incidence of Grade II-IV Acute Graft-versus-Host Disease. Started Jun 2002; status: completed.
02
Drugs
methoxsalen
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00054600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054600.